At ESMO 2025, AstraZeneca reported that Imfinzi plus BCG therapy reduced the risk of recurrence or death by 32% in patients ...

Learn how early regulatory engagement, validated digital systems, and robust protocol design enable biotechs to run parallel ...

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...

At ESMO 2025, Eli Lilly’s Verzenio and Novartis’ Kisqali both demonstrated durable efficacy in hormone receptor-positive, ...

In this week’s Applied Clinical Trials Brief, we highlight key findings from the 2025 State of the Industry Survey, explore how AI is transforming trial efficiency and patient engagement, and examine ...

Gain insight into why early toxicology readiness and strong scientific collaboration with CRO partners are critical to ...

See how early patient inclusion, integrated regulatory planning, and seamless CRO partnerships can help biotechs accelerate ...

Designing adhesion and durability for biopharmaceuticals in the most extreme cold chain environments.

Praxis Precision Medicines has shared positive data from its Phase III Essential3 clinical trial program (NCT06087276) assessing ulixacaltamide in essential tremor (ET). Across two studies, the small ...

Eli Lilly’s oral GLP-1 therapy, orforglipron, met all primary and key secondary endpoints in the Phase III ACHIEVE-2 and ACHIEVE-5 studies, showing significant A1C reduction, weight loss, and ...

Uncover how improving data accuracy and leveraging synthetic control arms can optimize trial efficiency, reduce costs, and generate stronger real-world insights.

As pharma wrestles with whether to trust fully autonomous AI, semi-autonomous agents are emerging as a safer middle ground that reduces manual work, eliminates white space in clinical development, and ...